More was spent by Novo Nordisk on shareholder enrichment in the form of stock buybacks and dividends than on R&D, a hallmark of the financialized pharmaceutical business model
In a survey, 5% of Americans said they would pay $1,000 or more per month for these drugs[5]
GLP-1 and GIP options may include Tirzepatide, Semaglutide, Mounjaro, Zepbound, Wegovy, and Ozempic when clinically appropriate
Give any protocol change at least 4 to 6 weeks before evaluating
Dosage and administration Available in various dosage forms, including subcutaneous solutions and injections, tirzepatide offers flexibility with strengths ranging from 2.5 mg to 15 mg
The discovery could help scientists preserve thirst by designing drugs that "target good places but not bad places," Daniels says